Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan (Can Do)
Diabetes Mellitus, Type 2

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria
- Able, in the opinion of the Investigator, and willing to give informed consent
- Age ≥ 25 years old
- Established T2DM (≥ 3 months) on stable dose monotherapy (metformin only for ≥ 8 weeks prior to enrolment) OR stable dose dual therapy (metformin plus either repaglinide, a sulphonylurea or pioglitazone or DPP-4 inhibitor for ≥ 8 weeks prior to enrolment)
- HbA1c between 6.6 - 11% (49mmol/mol - 97mmol/mol) at the screening visit
- Individuals intending to fast during the holy month of Ramadan
Exclusion Criteria
- Unable, in the opinion of the Investigator, and unwilling to provide informed consent
- Aged < 25 years old
- Established T2DM (≤ 3 months) on medication for fewer than 8 weeks prior to enrolment
- HbA1c ≤6.5 and ≥11.1%
- Individuals not intending to fast during the holy month of Ramadan
- Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods. The latter includes avoiding sex, hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel), or male partner sterilization, consistent with local regulations regarding use of birth control methods for subjects participating in clinical trials, for the duration of their participation in the study, or not heterosexually active. Furthermore, subjects who are not heterosexually active at screening must agree to utilize a highly effective method of birth control if they become heterosexually active during their participation in the study. Women of childbearing potential must have a negative urine pregnancy test at baseline.
- Suffer from terminal illness
- Have renal disease that requires immunosuppressive therapy, dialysis or transplant
- Have nephrotic syndrome or inflammatory renal disease
- Have an estimated glomerular filtration rate (eGFR) <60ml/min/1.73m2 at screening
- Have serum creatinine levels >132.6μmol/L for men or >123.8μmol/L for women
- Impaired liver function (ALAT ≥ 2.5 times upper limit of normal)
- Known Hepatitis B antigen or Hepatitis C antibody positive
- Clinically significant active cardiovascular disease (including history of myocardial infarction, unstable angina, previous revascularization procedure or cerebrovascular accident) within the past 6 months before screening
- Have uncontrolled hypertension (defined as systolic blood pressure ≥180mm/Hg and diastolic ≥100mm/Hg in the supine position after >5minutes rest with confirmed compliance to antihypertensive medication)
- Heart failure (NYHA class III and IV) at the discretion of the investigator
- Previous history of recurrent major hypoglycaemia as judged by the study clinician
- Known or suspected allergy to the study product
- Receipt of any investigational drug within four weeks prior to this study
- Has had previous treatment with a GLP-1 receptor agonist, insulin, or another SGLT2 inhibitor within 12 weeks of screening
- Have severe and enduring mental health problems
- Are not primarily responsible for their own care
- Are receiving insulin therapy
- Type 1 diabetes
- Any contraindication to sulphonylureas, repaglinide, pioglitazone and/or DPP-4 inhibitors
- Have severe irritable bowel disorder
- Have hereditary glucose-galactose malabsorption
- Have primary renal glycosuria
- Patients who have participated in another study of an investigational medicinal product in the last 3 months
- High risk of bone fracture (undiagnosed osteoporosis) as determined by the WHO FRAX tool
- Evidence of excessive and compulsive drinking of alcohol i.e. alcohol abuse as determined by the Fast Alcohol Screening Test (FAST)
- Individuals on a severe calorie restricted diet <800cals/day
- Has a surgical procedure booked in the next 12 months
- Has a history of chronic pancreatitis
- Has latent autoimmune diabetes in adults (LADA)
- Individuals on loop diuretics
- Any contraindication to the IMP
Sites / Locations
- University Hospitals of Leicester NHS Trust
- University Hospitals Birmingham NHS Foundation Trust
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Canagliflozin + Metformin
Repaglinide + Metformin
Pioglitazone + Metformin
Gliclazide + Metformin
Glimepiride + Metformin
Canagliflozin + metformin (using the participant's current dose, or dose recommended by the study clinician). An initial dose of 100mg once daily of Canagliflozin will be prescribed, and this will be titrated up to a maximum of 300mg once daily.
Repaglinide + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). An initial dose of 0.5mg once daily where no prior treatment has been given will be prescribed. However, where prior treatment has been in place, an initial dose of 1-2mg once daily will be started and this will be titrated up to a maximum dose of 4mg daily.
Piogliazone + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). For example, Pioglitazone dose will initially be 15mg or 30mg once daily. If the response is inadequate, the maximum daily dosage will be increased to 45mg once daily.
Gliclazide + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). For example, Gliclazide dose will initially be 40-80 mg once daily, up to maximum dose of 160mg twice daily..
Glimepiride + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). Glimepiride will initially be administered as 1mg once daily, up to a maximum dose of 4mg once daily.